The University of Kansas BRAIN Lab is conducting a research study to learn about behavioral and brain differences associated with the Fragile X premutation. Males and females ages 50-80 living with the Fragile X premutation, with or without FXTAS, may be eligible to participate. The study includes remote & in-person visits at the University of Kansas.
PureTech Health has been awarded a DOD grant of up to $11.4 million from the DOD for their trial of LYT-300, oral formulation of allopregnanolone, in people with Fragile X-associated tremor/ataxia syndrome (FXTAS).
Dr. Michelle Tosin, a 2022 NFXF Junior Investigator, summarizes the Diagnosis and Treatment of Fragile X-associated Tremor Ataxia Syndrome session at the 18th International Fragile X Conference.
Researchers at the University of Wisconsin explored the relationship between obtaining a college degree and the manifestation of the neurodegenerative symptoms of FXTAS among women at elevated genetic risk.
Researchers across several institutions set out to develop a revised version of the FXTAS-RS designed to specifically assess FXTAS motor signs.
This is the first time that Fragile X premutation carriers have been tracked in a longitudinal study. This study provides evidence for early markers of FXTAS that may be helpful in eventually identifying the best candidates for early, preventive intervention.
Explore examples of recent announcements and headlines focused on treatment development in Fragile X syndrome. Presented by Elizabeth Berry-Kravis, MD, PhD, and Craig A. Erickson, MD.
Learn in this webinar the pathological progression of several longitudinally followed patients with FXTAS at the UC Davis Fragile X Research and Treatment Center.
Explore this premutation webinar to learn more about Fragile X and Associated Tremor/Ataxia Syndrome (FXTAS) with our expert panel: Peter K. Todd, MD, Randi J. Hagerman, MD, David Hessl, PhD, and Dr. Deborah A. Hall, MD.
It's time for our 2022 FXS industry insights. Moderated by Hilary Rosselot, explore research, insights, clinical trials, discussions, and more with presentations by Stela Filipovic-Sadic from Asurage, Stephen O’Quinn from Zynerba Pharmaceuticals, Chad Coberly from Tetra Therapeutics, and Wayne Chadwick from Healx.
Being able to identify and diagnose possible nervous system disorders by detecting gait problems 15 to 20 years before their clinical diagnosis could help advance treatment development and quality of life.
This system could potentially predict FXTAS onset in premutation carriers who are not showing signs of FXTAS on a neurological exam.
The University of Kansas BRAIN Lab is conducting a research study to learn about behavioral and brain differences associated with the Fragile X premutation. Females with the premutation ages 55–80 may be eligible to participate.
